

COVID 19 TEST – VALIDATION OUTCOME

2 March 2021
Tunc Mert Sayin
Jiangsu Bioperfectus Technologies Co., Ltd

TC/HR/010321

Dear Tunc Mert Sayin

COVID 19 TEST - VALIDATION OUTCOME

Thank you for your ongoing co-operation and for providing us with the samples of the Bioperfectus Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit V2 that we requested for validation.

Your product progressed through phase 3A validation and has been examined at a Design Authority Review (DAR). We would like to advise you that the Bioperfectus Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit V2 was successful in the phase 3A validation and that the Bioperfectus Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit V2 showed no drop off in sensitivity when compared with the wild type with respect to the following variants - VOC1 Kent, UK, B.1.1.7 and VOC2 South Africa, B.1.351.

We will continue to evaluate the Bioperfectus Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit V2 against future variants as and when they arise, and we will report the results of any future validation to you.

CONFIDENTIALITY

We remind you of your ongoing obligations of confidentiality as set out in the non-disclosure agreement signed by you dated 21 August 2020.

We thank you for your continued interest in supporting our COVID-19 response

Yours sincerely,

NHS Test and Trace